Companies
(73)
AAC Clyde Space
ALM Equity
Alzinova
Arion Bank
Arlandastad Group
Ascelia Pharma
Bactiguard
Bergman & Beving
Besqab
BioPorto
Björn Borg
Bokusgruppen
Bonava
BTS Group
Byggmästaren
CAG Group
Calviks
Carasent
CDON
Clavister
Clemondo Group
eEducation Albert
Elanders
Elicera Therapeutics
Eolus
Ependion
EQL Pharma
Faron Pharmaceuticals
FluoGuide
Gentoo Media
GiG Software
HAKI Safety
HANZA
Iconovo
Idun Industrier
InfraCom
Initiator Pharma
Intervacc
ITAB Group
Kebni
Lifecare ASA
Lindex Group
Logistri
Lumi Education Group
Lytix Biopharma
Medivir
Mentice
Micro Systemation
MilDef Group
Net Insight
Nordic LEVEL Group
Orexo
Ortoma
OssDsign
Paxman
Pierce
PowerCell
Pricer
Qualisys
Relais Group
SaltX
Scanfil
Sensys Gatso Group
Sleep Cycle
Solar Foods
Spago Nanomedical
Svedbergs Group
Taaleri
Terranor
Vertiseit
Vivesto
W5 Solutions
Waystream
Sweden
Healthcare
Near term
6-12 MONTHS
Key near-term drivers of the equity story include clinical progress, potentially de-risking study readouts and potential partnering transactions that could provide external validation and generate income. We view the VBX-1000 readout in Q1 2027 as the most important near-term catalyst. Positive data could further reduce development risk and materially strengthen the case for a third-party partnering agreement in 2027. Beyond this year, we see the FLEX-HCC readout, expected in H2 2027, as the catalyst with the greatest potential impact on the shares.
Long term
6+ YEARS
The longer-term story centres on Medivir advancing its pipeline towards regulatory approval and commercialisation. With three mid-stage assets targeting four indications, the company has reduced its reliance on a single programme and its exposure to asset-specific risk. A stronger shareholder base and improved financial position provide additional support for further development. We expect potentially registrational data readouts across key programmes within the next four to five years. Positive results could support regulatory submissions and, subject to approval, partnering and successful commercial execution, establish a path towards sustained profitability.
Development risks remain significant, with its clinical assets in mid-stage development
Valuation rests on three assets and any clinical setbacks would have material effects on our valuation
Despite its strengthened financials, it is likely Medivir will need to raise additional capital to support further development of its programmes
A licensing agreement for fostrox or MIV-711 would represent a considerable upside to our valuation
Price
Fair range high value
Fair range low value
The upper end of our fair value range is derived from our SOTP analysis using a WACC of 12%, while the lower end is based on a 15% discount rate, reflecting continued risk aversion towards the biotechnology sector. The upper end assumes a gradual normalisation of investor sentiment and a more supportive valuation environment.
Our valuation of Medivir is based on a SOTP model, where we assess each project over its patent lifespan. We include only projects with a clear path forward, whether driven by the company or a partner. For now, we have included fostrox, MIV-711 and MIV-701. Our forecasts are risk-adjusted according to the respective development phases.
About DNB Carnegie Access
DNB Carnegie Access aim is to connect listed companies with the capital markets. Through top ranked public equity research and broad distribution via written reports, seminars, video, and podcasts, we increase visibility and investor understanding for small- and medium-sized companies, both among institutional and private investors.
Along with corporate finance, market making and certified advisory we provide a complete product offering to our clients.
Private Banking
Tailored wealth management. Your financial future, personalized.
Montrose
A digital investment platform designed for passionate investors.
DNB Carnegie
Leading Nordic investment bank and wealth management.
© Copyright DNB Carnegie Investment Bank AB